Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B7-H3 CAR T Cells in Recurrent, Platinum-Resistant Ovarian Tumors
NCT06646627Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of B7H3-CART in ovarian cancer (2 arms), sponsored by Stanford University. Primary endpoints: Feasibility of B7-H3CART Manufacturing at 2 years and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) at 28 days. Started Nov 2024; status: recruiting.
02
Drugs
B7H3-CART
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06646627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646627.